Alpha Tau Medical (DRTS) director discloses shares, RSUs and options
Rhea-AI Filing Summary
Alpha Tau Medical Ltd. director Blumenfeld S. Morry filed an initial Form 3 reporting his existing equity position. He directly holds 155,771 Ordinary Shares of Alpha Tau Medical and 4,680 Restricted Share Units, which will vest in full on the earlier of one year from March 9, 2026 or the next Annual General Meeting of Shareholders, subject to his continued service.
He also reports multiple option grants over Ordinary Shares at exercise prices ranging from $2.98 to $11.50 per share, with expirations between 2028 and 2036. Footnotes indicate that some options are already fully vested, while others will vest in their entirety on the same schedule tied to March 9, 2026 or the next Annual General Meeting.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Options | -- | -- | -- |
| holding | Options | -- | -- | -- |
| holding | Options | -- | -- | -- |
| holding | Options | -- | -- | -- |
| holding | Options | -- | -- | -- |
| holding | Options | -- | -- | -- |
| holding | Options | -- | -- | -- |
| holding | Options | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
| holding | Restricted Share Units | -- | -- | -- |
Footnotes (3)
- F1. These ordinary shares represent restricted share units, which will vest in their entirety upon the earlier of: one year commencing from March 9, 2026 or the next Annual General Meeting of Shareholders, subject to the Reporting Person's continued service.
- F2. These are options to acquire ordinary shares, which have fully vested as of the date hereof.
- F3. These are options to acquire ordinary shares, which options will vest in their entirety upon the earlier of: one year commencing from March 9, 2026 or the next Annual General Meeting of Shareholders, subject to the Reporting Person's continued service.
AI-generated analysis. How Rhea-AI works. Not financial advice.
